{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:15:09Z","timestamp":1768900509895,"version":"3.49.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Key Scientific and Technological Research Plan of the Hebei Health and Health Commission","award":["20241497"],"award-info":[{"award-number":["20241497"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,16]]},"abstract":"<jats:p>Ketorolac tromethamine is a potent nonsteroidal anti-inflammatory drug commonly used to treat moderate-to-severe pain, especially in the context of postoperative and acute injury. However, real-world studies on the adverse events (AEs) associated with ketorolac tromethamine remain limited. A disproportionality analysis was performed using data from the FDA Adverse Event Reporting System between January 2004 and September 2024 to evaluate the safety profile of ketorolac tromethamine by analyzing the demographic characteristics and timing of AEs. A total of 3655 AEs associated with ketorolac tromethamine were identified, revealing 167 significantly preferred terms and 2 notable system organ classes. Commonly reported AEs included drug hypersensitivity, hypersensitivity reactions, and eye irritation. Subgroup analyses indicated that eye disorders and immune system disorders were significant across gender, age, and weight categories. Weibull analysis showed that the occurrence of AEs decreases over time, suggesting early failure. Sensitivity analyses identified eye and immune system disorders as the main safety concerns for ketorolac tromethamine, with persistent issues in both categories after ophthalmic use and immune disorders after systemic use. This study confirmed known AEs associated with ketorolac tromethamine while identifying additional risks, particularly those related to eye and immune system disorders. Continued monitoring of these AEs in clinical settings is essential to ensure patient safety.<\/jats:p>","DOI":"10.1097\/md.0000000000047288","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:00:41Z","timestamp":1768849241000},"page":"e47288","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A real-world signal detection analysis uncovering the safety profile of ketorolac tromethamine"],"prefix":"10.1097","volume":"105","author":[{"given":"Yuanyuan","family":"Rong","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Fourth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaqin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2467-4255","authenticated-orcid":false,"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260119","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/papr.12198","article-title":"Ketorolac tromethamine \u2013 routes and clinical implications.","volume":"15","author":"Vadivelu","year":"2015","journal-title":"Pain Pract"},{"key":"R2-20260119","first-page":"288","article-title":"Ketorolac tromethamine.","volume":"55","author":"Jay","year":"1991","journal-title":"Conn Med"},{"key":"R3-20260119","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/SAP.0000000000001409","article-title":"Ketorolac and hematoma incidence in postmastectomy implant-based breast reconstruction.","volume":"80","author":"Mikhaylov","year":"2018","journal-title":"Ann Plast Surg"},{"key":"R4-20260119","first-page":"CD012294","article-title":"Ketorolac for postoperative pain in children.","volume":"7","author":"McNicol","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20260119","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1007\/s12325-024-02933-7","article-title":"A novel formulation of ketorolac tromethamine (NTM-001) in continuous infusion in adults with and without renal impairment: a randomized controlled pharmacologic study.","volume":"41","author":"Pergolizzi","year":"2024","journal-title":"Adv Ther"},{"key":"R6-20260119","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000323881","article-title":"Mechanisms of drug toxicity or intolerance.","volume":"29","author":"Egan","year":"2011","journal-title":"Dig Dis"},{"key":"R7-20260119","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2015.12.017","article-title":"Adverse drug reactions and organ damage: the liver.","volume":"28","author":"Licata","year":"2016","journal-title":"Eur J Intern Med"},{"key":"R8-20260119","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2125.2011.03933.x","article-title":"General principles of investigating and managing drug allergy.","volume":"71","author":"Frew","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R9-20260119","doi-asserted-by":"crossref","first-page":"107832","DOI":"10.1016\/j.yebeh.2021.107832","article-title":"Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS).","volume":"117","author":"Kamitaki","year":"2021","journal-title":"Epilepsy Behav"},{"key":"R10-20260119","doi-asserted-by":"crossref","first-page":"e00341","DOI":"10.1002\/prp2.341","article-title":"Adverse drug reactions of montelukast in children and adults.","volume":"5","author":"Haarman","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"R11-20260119","doi-asserted-by":"crossref","first-page":"e25221","DOI":"10.1371\/journal.pone.0025221","article-title":"Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting.","volume":"6","author":"Anderson","year":"2011","journal-title":"PLoS One"},{"key":"R12-20260119","doi-asserted-by":"crossref","first-page":"119010","DOI":"10.1016\/j.jep.2024.119010","article-title":"Ginkgo biloba extract safety: insights from a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.","volume":"337","author":"Yao","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"R13-20260119","doi-asserted-by":"crossref","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system.","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"key":"R14-20260119","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14740338.2024.2327502","article-title":"Hemorrhage induced by antithrombotic agents: new insights from a real-world pharmacovigilance study.","volume":"23","author":"Guo","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R15-20260119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2017-0437","article-title":"Adverse event reporting in clinical trials: time to include duration as well as severity.","volume":"23","author":"Sartor","year":"2018","journal-title":"Oncologist"},{"key":"R16-20260119","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fphys.2014.00332","article-title":"Patient stratification and identification of adverse event correlations in the space of 1190 drug related adverse events.","volume":"5","author":"Roitmann","year":"2014","journal-title":"Front Physiol"},{"key":"R17-20260119","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1089\/jop.2023.0066","article-title":"Preformulation-assisted design of ketorolac tromethamine for effective ophthalmic delivery.","volume":"39","author":"Abdelkader","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"R18-20260119","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1517\/14740338.2012.635141","article-title":"Drug safety evaluation of intravitreal triamcinolone acetonide.","volume":"11","author":"Veritti","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"R19-20260119","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jop.2020.0089","article-title":"Pre-emptive topical ketorolac tromethamine 0.5% for panretinal photocoagulation.","volume":"37","author":"Chewa Raja","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"key":"R20-20260119","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijpharm.2015.09.058","article-title":"Ocular safety comparison of non-steroidal anti-inflammatory eye drops used in pseudophakic cystoid macular edema prevention.","volume":"495","author":"Fern\u00e1ndez-Ferreiro","year":"2015","journal-title":"Int J Pharm"},{"key":"R21-20260119","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1034\/j.1600-0420.2001.079002177.x","article-title":"Randomised controlled trial of ketorolac in the management of corneal abrasions.","volume":"79","author":"Goyal","year":"2001","journal-title":"Acta Ophthalmol Scand"},{"key":"R22-20260119","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1517\/17425247.2013.743528","article-title":"Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets.","volume":"10","author":"Vemula","year":"2013","journal-title":"Expert Opin Drug Deliv"},{"key":"R23-20260119","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijpharm.2014.08.023","article-title":"Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan.","volume":"474","author":"Li","year":"2014","journal-title":"Int J Pharm"},{"key":"R24-20260119","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/jop.2015.0021","article-title":"Safety and efficacy of intravitreal preservative-free triamcinolone acetonide (triesence) for macular edema.","volume":"31","author":"Chang","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"R25-20260119","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3928\/01913913-20100920-01","article-title":"Effectiveness of ketorolac tromethamine in prevention of severe retinopathy of prematurity.","volume":"48","author":"Giannantonio","year":"2011","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R26-20260119","first-page":"1","article-title":"Signal mining of adverse reactions in the antiemetic drug ondansetron during pregnancy: a real-world analysis of the FDA adverse event reporting system (FAERS).","author":"Chen","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R27-20260119","doi-asserted-by":"crossref","first-page":"T20","DOI":"10.1016\/j.farma.2022.12.007","article-title":"Prevalence of adverse drug reactions associated with emergency department visits and risk factors for hospitalization.","volume":"47","author":"Brandariz-N\u00fa\u00f1ez","year":"2023","journal-title":"Farm Hosp"},{"key":"R28-20260119","doi-asserted-by":"crossref","first-page":"2417399","DOI":"10.1080\/20523211.2024.2417399","article-title":"Pharmacovigilance: the evolution of drug safety monitoring.","volume":"17","author":"Khan","year":"2024","journal-title":"J Pharm Policy Pract"},{"key":"R29-20260119","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40264-017-0509-2","article-title":"Causality assessment in pharmacovigilance: still a challenge.","volume":"40","author":"Ralph Edwards","year":"2017","journal-title":"Drug Saf"},{"key":"R30-20260119","doi-asserted-by":"crossref","first-page":"1426323","DOI":"10.3389\/fphar.2024.1426323","article-title":"A discovery and verification approach to pharmacovigilance using electronic healthcare data.","volume":"15","author":"Dijkstra","year":"2024","journal-title":"Front Pharmacol"},{"key":"R31-20260119","doi-asserted-by":"crossref","first-page":"1517616","DOI":"10.3389\/fphar.2025.1517616","article-title":"Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system.","volume":"16","author":"Yang","year":"2025","journal-title":"Front Pharmacol"},{"key":"R32-20260119","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/alr.22516","article-title":"Aspirin-exacerbated respiratory disease: longitudinal assessment of a large cohort and implications of diagnostic delay.","volume":"10","author":"Kshirsagar","year":"2020","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:00:45Z","timestamp":1768849245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047288","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"2025-08-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}